Satellos Bioscience (MSLE) Current Assets (2023 - 2026)
Satellos Bioscience (MSLE) posted quarterly Current Assets of $75.2 million for Q1 2026, up 135.91% quarter-over-quarter from $31.9 million in Q4 2025.
Satellos Bioscience (MSLE) Current Assets (2023 - 2026) Analysis & Trends
Satellos Bioscience (MSLE) has reported Current Assets for 4 consecutive years, with $75.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets changed N/A year-over-year to $75.2 million; the TTM figure through Mar 2026 stood at $75.2 million (changed N/A YoY), while the FY2025 annual figure was $31.9 million, down 37.17% from the prior year.
- Current Assets improved to $75.2 million in Q1 2026 per MSLE's latest filing, from $31.9 million in the prior quarter.
- Across five years, Current Assets topped out at $75.2 million in Q1 2026 and bottomed at $29.6 million in Q4 2023.
- Historically, Current Assets has averaged $47.2 million across 4 years, with a median of $42.1 million in 2024.
- Annual changes were most pronounced in 2024 — Current Assets soared 76.47% — and 2025, when it sank 39.0%.
- Satellos Bioscience's Current Assets stood at $29.6 million in 2023, then jumped by 76.47% to $52.3 million in 2024, then sank by 39.0% to $31.9 million in 2025, then jumped by 135.91% to $75.2 million in 2026.
- Business Quant data shows MSLE's Current Assets at $75.2 million in Q1 2026, $31.9 million in Q4 2025, and $52.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Satellos Bioscience | 208.31 Mn | 208.31 Mn | - | 65.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 75.22 Mn |
| Dec 31, 2025 | 31.88 Mn |
| Dec 31, 2024 | 52.27 Mn |
| Dec 31, 2023 | 29.62 Mn |